In the last 11 years as a principal investigator, I have had the honour to work with 33 talented female scientists. All of them have contributed to our results and made sure of our little success. 6 of them are now principal investigators, 6 are Ph'D students, 6 are PDRA, 5 are research fellow, 4 are mums, 2 are senior managers, 1 is a senior scientist, 1 is an editor, 1 is an NGO scientist, and 1 is a medical writer. All of them are active scientists! Thank you for your effort and patience to work with me and I wish you the best of luck for your future endeavours!
It' s with great honour to have been selected as one of the 329 EU researchers awarded an ERC Consolidator Grant. This grant will enable to expand our efforts in targeting Gliomas using our chemotactic and super-selective platform. I would like to thank all the members of the group who have generated the enabling work, the department and college for the support for the grant and interview preparation.
Chiara Cursi originally from Pisa in Italy has just started her PhD working on multivalent targeting within the Centre for Doctoral Training in Molecular Modelling & Materials Science, UCL and co-sponsored by MedImmune. Chiara is a biologist by training and with a strong background in immunology. She worked 3yrs as a research associate in Oxford before deciding to join us.
It is a great pleasure to welcome Safa to the group. She's started a PhD on chemotactic vesicles where she will be studying how asymmetric vesicles propel, interact one another and move in complex environments. Safa got her MSc in Pharmaceutical Chemistry from Queens Mary College London and she's originally from Bahrain.
This summer all the last year Ph'D student presented their work and our own Senio was awarded the Erwin Prize for best presentation in the Physical Chemistry Section. Well Done!
One more addition to our group comes from Granada (via the Imperial College). We welcome Belén Sola to our group who will be undertaking a PhD project sponsored by the Children with Cancer Research UK and will involve the formulation and delivery of combination therapy for the treatment of paediatric gliomas
Web-design: G. Battaglia